Recurrent Waldenstrom Macroglobulinemia: Clinical Trials

8 trials for Recurrent Waldenstrom Macroglobulinemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 3 terminated, 1 active not recruiting, 1 recruiting. 8 Phase 2, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 28Completed 3, Terminated 3, Active not recruiting 1, Recruiting 1
Phase 14Completed 2, Active not recruiting 1, Recruiting 1

Follow Recurrent Waldenstrom Macroglobulinemia: new trials by email Literature Review of Recurrent Waldenstrom Macroglobulinemia trials Research Report on Recurrent Waldenstrom Macroglobulinemia

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
ABBV-383 for the Treatment of Relapsed Refractory Waldenström Macroglobulinemia
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia
Phase 1 / Phase 2RecruitingMayo Clinic382026-09-302026-10-05
Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
Ibrutinib, Ixazomib Citrate, Laboratory Biomarker Analysis - Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia
Phase 2TerminatedMayo Clinic212018-08-142026-05-05
Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
Carfilzomib, Laboratory Biomarker Analysis, Rituximab - Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma
Phase 2TerminatedUniversity of Washington42017-12-182020-01-18
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Phase 2TerminatedFred Hutchinson Cancer Center1502017-09-112026-05-14
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
Selinexor - Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma
Phase 1 / Phase 2Active not recruitingBarbara Ann Karmanos Cancer Institute432017-06-202026-10-23
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Laboratory Biomarker Analysis, Lenalidomide, Nivolumab - Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma
Phase 1 / Phase 2CompletedDavid Bond, MD362017-02-142026-09-23
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Ibrutinib, Idelalisib, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia
Phase 2CompletedMayo Clinic652015-02-192026-06-24
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma
Bortezomib, Dexamethasone, Laboratory Biomarker Analysis - Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
Phase 1 / Phase 2CompletedNational Cancer Institute (NCI)92011-07-202021-10-04

Narrower conditions

Waldenstrom Macroglobulinemia (8)  ·  Lymphoma, B-Cell, Marginal Zone (5)  ·  Lymphoma, Follicular (4)  ·  Lymphoma, Mantle-Cell (4)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (3)  ·  Lymphoma, Large B-Cell, Diffuse (3)  ·  Lymphoma, B-Cell (2)  ·  Lymphoma, Non-Hodgkin (2)  ·  Blastic Plasmacytoid Dendritic Cell Neoplasm (1)  ·  Burkitt Lymphoma (1)  ·  Hematologic Diseases (1)  ·  Hodgkin Disease (1)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)  ·  Leukemia, Myeloid, Acute (1)  ·  Leukemia, Prolymphocytic (1)

Broader conditions

Blood Protein Disorders (8)  ·  Cardiovascular Diseases (8)  ·  Hemic and Lymphatic Diseases (8)  ·  Hemorrhagic Disorders (8)  ·  Hemostatic Disorders (8)  ·  Immune System Diseases (8)  ·  Immunoproliferative Disorders (8)  ·  Lymphatic Diseases (8)  ·  Lymphoproliferative Disorders (8)  ·  Neoplasms (8)  ·  Neoplasms by Histologic Type (8)  ·  Neoplasms, Plasma Cell (8)  ·  Paraproteinemias (8)  ·  Vascular Diseases (8)  ·  Hematologic Diseases (7)

Interventions

CT-P10 (2)  ·  Rituximab (2)  ·  Sirolimus (2)  ·  ibrutinib (2)  ·  Biopsy (1)  ·  Bortezomib (1)  ·  Calcium Dobesilate (1)  ·  Cyclophosphamide (1)  ·  Cyclosporine (1)  ·  Cyclosporins (1)  ·  Dexamethasone (1)  ·  Lenalidomide (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Mycophenolic Acid (1)  ·  Nivolumab (1)

Sponsors

Mayo Clinic (3)  ·  Barbara Ann Karmanos Cancer Institute (1)  ·  David Bond, MD (1)  ·  Fred Hutchinson Cancer Center (1)  ·  National Cancer Institute (NCI) (1)  ·  University of Washington (1)

Countries

United States (8)

Top investigators

Asher A. Chanan-Khan, M.D. (1)  ·  David Bond, MD (1)  ·  Dipenkumar Modi, M.D. (1)  ·  Leonard T Heffner (1)  ·  Masumi Ueda Oshima (1)  ·  Prashant Kapoor, MD (1)  ·  Stephen Smith (1)  ·  Wei Ding (1)

Results publications

PMID 28424162, PMID 33785483, PMID 41043099

NIH funding

P30CA015704 (2), P01CA078902 (1), P30CA022453 (1), P50CA097274 (1), U10CA021115 (1), U10CA180820 (1)